Hence, our results indicate that PFKFB3 inhibition by 3PO could be a potential therapeutic target in human RC, reducing cancer cell survival in vitro and inducing TVN in vivo, which ultimately may improve the currently established therapy to increase the rate of clinical complete responses. This evidence concerns the gene PFKFB3 and cancer.